Biosimilars Conference 2015

This conference discusses biosimilars in the EU and internationally, with a focus on both regulatory and scientific challenges as well as market access and experiences.

Back to Agenda

Session 1 Biosimilars and Non-Originator Biologics (NOBs) Market Developments

Session Chair(s)

Steffen Thirstrup, MD

Chief Medical Officer, European Medicines Agency, Netherlands

Biosimilar market is developing both in Europe and globally with an increasing demand for biotherapeutics. The first biosimilar was approved in the EU in 2006 and FDA approved the first in in the US in early March this year. The session looks into the trends in different regions over the past years and also discusses the market access and pricing.

Speaker(s)

Global Market Development of Biosimilars and Non-Originator Biologics in Emerging Markets

Per Troein, MBA, MSc

VP Strategic Partners, IQVIA, United Kingdom

Outcome of the October EC workshop on Access to and Uptake of Biosimilars

Hilda Juhász

Policy Officer, European Commission, Belgium

European Generics and Biosimilar Medicines Association's view on market developments

Pieter Dylst, DrPH, MPharm, RPh

Senior Manager Market Access & Value Added Medicines, Medicines For Europe, Belgium

European Biopharmaceutical Enterprises and EFPIA's view on market developments

Alexander Roediger, MA, MBA

Executive Director EMEAC Oncology Policy, MSD Sharp and Dohme GmbH, Switzerland